The FDA has approved expanded use of Sanofi Pasteur’s MenQuadfi, a meningococcal conjugate vaccine for children aged 2 to 10.
MenQuadfi is now the first quadrivalent conjugate vaccine licensed in the U.S. to prevent meningococcal disease in this age group, according to a news release from the agency.
Originally approved in 2005 for individuals aged 11 to 55, the vaccine protects against four major serogroups: A, C, Y and W-135.
The FDA’s decision was supported by two large clinical trials demonstrating the vaccine’s safety and immunogenicity in younger children. The studies also showed stronger immune responses compared to Menomune, a polysaccharide vaccine.
The expanded approval comes amid ongoing concern over meningococcal disease, a rapidly progressing bacterial infection that affects up to 2,800 people in the U.S. each year, according to the release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
